Baselga Jose
Oncology Program, Vall d'Hebron University Hospital and Vall d'Hebron Research Institute, Universidad Autónoma de Barcelona, Barcelona 08035, Spain.
Science. 2006 May 26;312(5777):1175-8. doi: 10.1126/science.1125951.
One of the most exciting developments in cancer research in recent years has been the clinical validation of molecularly targeted drugs that inhibit the action of pathogenic tyrosine kinases. Treatment of appropriately selected patients with these drugs can alter the natural history of their disease and improve survival. The clinical validation of these "first-generation" tyrosine kinase inhibitors has been the prelude to a second wave of advances in molecular targeting that is expected to further change the way we classify and treat cancer. Efforts are now being directed at identifying the tumor subtypes and patients who will benefit the most from these drugs. In addition, new compounds that circumvent acquired resistance to the first-generation tyrosine kinase inhibitors are being tested in patients with refractory disease. Agents directed against new molecular targets are also being explored.
近年来癌症研究中最令人兴奋的进展之一，是抑制致病性酪氨酸激酶作用的分子靶向药物的临床验证。用这些药物治疗经过适当选择的患者，可以改变其疾病的自然病程并提高生存率。这些“第一代”酪氨酸激酶抑制剂的临床验证，是分子靶向治疗第二波进展的前奏，预计这将进一步改变我们对癌症的分类和治疗方式。目前正在努力确定最能从这些药物中获益的肿瘤亚型和患者。此外，针对第一代酪氨酸激酶抑制剂产生获得性耐药的新化合物正在难治性疾病患者中进行测试。针对新分子靶点的药物也在探索之中。
